Overview of congress submissions from 2014

The following submissions were presented at international congresses in 2014 by members of the German Breast Group:

Loi S, Savas P, Lonnstedt I, Fumagalli D, Caramia F, Li J, Salgado R, Rowan A, Andre F, Denkert C, Neven P, Loibl S, Sotiriou C, Swanton C, Speed TP: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT). Poster discussion (PD3-1).

Loibl S, Darb-Esfahani S, Klimowicz A, von Minckwitz G, Lederer B, Huober J, Hartmann A, Eidtmann H, Pfitzner BM, Fasching PA, Tiemann K, Jackisch C, Mehta K, Untch M, Denkert C: PTEN and PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer. Poster discussion (PD5-7).

Witzel I, Laakmann E, Fehm T, Möbus V, vonMinckwitz G, Kaiser J, Loibl S, Müller V: Brain metastases in breast cancer network Germany (BMBC, GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from breast cancer patients with brain metastases. Poster Session (OT2-5-01)

Untch M, Jackisch C, Schneeweiß A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S, von Minckwitz G: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solventbased paclitaxel followed by anthracyline/ cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. Oral presentation (S2-07).

von Minckwitz G, Reimer T, Potenberg J, Conrad B, Schürer U, Eidtmann H, Just M, Paepke S, Stickeler E, Heinrich G, Untch M, Moebus V, Thomssen C, Jackisch C, Huober J, Loibl S, Nekljudova V, Nitz U: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Oral presentation (S3-04).

Loibl S, Brase JC, Gade S, Huober J, Krappmann K, Engels K, Fend F, Pfitzner BM, Hilfrich J, Thomssen C, Holzhausen HJ, Darb-Esfahani S, Schem C, Mehta K, Kronenwett R, von Minckwitz G, Denkert C: Predicting residual risk of recurrence after neoadjuvant chemotherapy- a retrospective analysis of EndoPredict® in the GeparTrio trial. Poster Session (P3-06-12).

Avril S, von Minckwitz G, Gündisch S, Gade S, Malinowsky K, Fasching PA, Karn T, Hartmann A, Untch M, Denkert C, Becker K-F, Loibl S: Assessment of phosphorylated HER2 protein as predictive biomarker to stratify anti-HER2 treatment in HER2 non-amplified patients - A translational study in the GeparQuattro and GeparQuinto trials. Poster Session (P3-06-36).

Gerber B, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J-U, Hauschild M, Fehm T, Nekljudova V, von Minckwitz G: Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of The HER2-negative cohort of the GEPARQUINTO study (GBG 44). Poster Session (P3-11-01).

Witzel I, Matschke J, Glatzel M, Milde-Langosch K, Laakmann E, Loibl S, Pfitzner BM, Denkert C, Müller V: SPARC expression in brain metastases of breast cancer patients. Poster Session (P6-16-09).

Kern P, von Minckwitz G, Pütter C, Flach A, Pavlidou S, Kimmig R, Rezai M: Stage-related risk categorization and influence of free margins on survival in triple negative early breast cancer - a population-based study of 2037 TNBC patients with adjuvant chemotherapy. Poster Session (P2-13-01).

Puglisi F, Cortes J, Vrdoljak E, Gligorov J, Marschner N, Zielinski C, de Laurentiis M, Brain E, Lévy C, Welt A, Kahan Z, Inbar M, de Ducla S, Freudensprung U, von Minckwitz G: Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Poster discussion (PD2-4).

Cortes J, Vrdoljak E, Puglisi F, Marschner N, Gligorov J, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, Veyret C, Fontana A, Oestergaard M, de Ducla S, Freudensprung U, von Minckwitz G: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC). Poster Session (P3-06-08).

Halfter KML, Ditsch N, Kolberg H-C, Fischer H, Hauzenberger T, Edler von Koch F, Bauerfeind I, von Minckwitz G, Funke I, Crispin A, Mayer B: Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy - The SpheroNEO study. Poster Session (P3-06-13).

Hanusch C, Schneeweiss A, Untch M, Paepke S, Kümmel S, Jackisch C,Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer JU, Loibl S, Burchardi N, von Minckwitz G: Dual blockade with Afatinib and Trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 – efficacy and safety analysis. Oral presentation, Abstract Nr. 255O

Noeding St., Forstbauer H., Wachsmann G., Ober A., Schneeweiss A., Christensen B., von Abel E., Grischke EM., Höffkes H.G., Klare P., Ko YD., Schmatloch S., Burchardi N., Loibl S., von Minckwitz G., Möbus V: GAIN2: Adjuvant phase III trial comparing an intensified dose-dense adjuvant therapy with EnPC compared to a dose-dense, dose-adapted therapy with dtEC dtDocetaxel in patients with primary breast cancer and a high risk of recurrence. Poster Discussion, Abstract Nr 264PD

Loibl S, De La Haba J. R., von Minckwitz G, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin Jimenez M: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the GEICAM/GBG LEA study. Safety analysis. Poster Discussion, Abstract Nr 323PD

Han S. N., Amant F, Sangalli C, Loibl S, Gheysens O, Lok C. A., Dahl K, Steffensen K, Halaska M. J., Peccatori F, Gentilini O: Sentinel lymph node biopsy for breast cancer treatment during pregnancy - on behalf of the International Network of Cancer, Infertility and Pregnancy (INCIP) and the German Breast Group (GBG). Poster Discussion, Abstract Nr 266PD_PR

Ataseven B, Blohmer J, Denkert C, Gerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G: Impact of multifocal or multicentric disease on surgical, locoregional, and distant survival after neoadjuvant chemotherapy in 3562 breast cancer patients. Poster Discussion, Abstract Nr 321PD

Sinn B, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H, Mehta K, Loibl S: Mucin-1 protein and mRNA expression in breast cancer patients treated with neoadjuvant chemotherapy. Best abstracts session, Abstract Nr 8O

Moebus V, von Minckwitz G, Jackisch C, Lueck HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, Schmidt M, Loibl S, Nekljudova V, Untch M, Thomssen C: German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis. J Clin Oncol 32:5s, 2014 (suppl; abstr 1009), ASCO 2014

von Minckwitz G, Hahnen E, Fasching PA, Hauke J, Schneeweiss A, Salat C, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kummel S, Eidtmann H, Paepke S, Nekljudova V, Loibl S, Untch M, Schmutzler R, GBG and AGO-B Study Groups: Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. J Clin Oncol 32:5s, 2014 (suppl; abstr 1005), ASCO 2014

Fontanella C, Gade S, von Minckwitz G, Lederer B , Blohmer JU, Costa SC, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Loibl S; German Breast Group: Prognostic score for Luminal A-like breast cancer patients. J Clin Oncol 32:5s, 2014 (suppl; abstr 525), ASCO 2014

Denkert C, von Minckwitz G, Brase J, Darb-Esfahani S, Gade S, Kronenwett R, Salat C, Loi S, Schem C, Sotiriou C, Mehta K, Klare P, Fisch K, Blohmer JU, Tesch H, Kümmel S, Krappmann K, Dietel M, Untch M, Loibl S: Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. Clin Oncol 32:5s, 2014 (suppl; abstr 510) ASCO 2014

Loibl S, Han S, Mayer K, MacMillan K, Gyapong S, Luebbe K, Weiss C, Schreiber K, Witzel I, Müller V, Schneeweiss A, Mundhenke C, Waldhoer C, Rezek D, Vogt N, Strobel S, Parokonnaya A, Nekljudova V, Amant F, von Minckwitz G: Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP). J Clin Oncol 32:5s, 2014 (suppl; abstr 1071), ASCO 2014

von Minckwitz G, O'Shaughnessy J, Winer E.P., Wolmark N, Geyer CE, Huober J, Loibl S, Sikov W.M., Untch M, McKee M, Giranda V, Rugo H: Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1149) ASCO 2014

Andre F, Daly F, Azim H, Agrapart V, Goulioti T, Pinto A, Saba C, Guitart M, Turner N, Pierrat JM, Loibl S, Chesnel T, Curigliano G, Loi S, Piccart-Gebhart M, Cortes J: FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1134) ASCO 2014

Marinovich M, Houssami N, Macaskill P, von Minckwitz G, Blohmer JU, Irwig L: Accuracy of ultrasound during neoadjuvant therapy for breast cancer to predict pathologic response. J Clin Oncol 32:5s, 2014 (suppl; abstr 1089), ASCO 2014

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kuehn T: Validation of a nomogram predicting nonsentinel lymphnode metastases among patients with breast cancer after neoadjuvant chemotherapy (NACT): A transSENTINA substudy. J Clin Oncol 32, 2014 (suppl; abstr e12022), ASCO 2014

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kuehn T: Development of a novel nomogram predicting nonsentinel lymph node metastases among patients with breast cancer after neoadjuvant chemotherapy (NACT): A transSENTINA substudy. J Clin Oncol 32:5s, 2014 (suppl; abstr 1100), ASCO 2014

Mamounas E, Cortazar P, Zhang L, von Minckwitz G, Mehta K, Cameron D. A, Bonnefoi H.R., Gianni L, Valagussa P, Wolmark N, Loibl S, Bogaerts J, Swain S. M., Sridhara R, Costantino J. P., Rastogi P, Geyer C. E., Eidtmann H, Gerber B, Untch M: Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). J Clin Oncol 32, 2014 (suppl 26; abstr 61)

Linderholm B.K., von Minckwitz G., Caramuta S., André F., Sotiriou C., Cerone M., Schwenkglenks M., Blank P., Denkert C., Gade S. and Loibl S. on behalf of the German Breast Group (GBG) neoadjuvant board and the RESPONSIFY consortium (EU FP7- HEALTH Collaborative project): Serum-Vascular Endothelial Growth Factors (sVEGF) A and C have a potential as predictive tests for neoadjuvant bevacizumab in primary breast cancer. Poster presentation, Abstract Nr. 896, AACR 2014

von Minckwitz G, Conrad B, Decker T, Reimer T, Hackmann J, Potenberg J, Bauer W, Jackisch C, Nekljudova V, Loibl S: Final results froma randomisedphase II study comparing epirubicinplus cyclophosphamide(EC)or CMF versus nabpaclitaxel plus capecitabine(PX)as adjuvant chemotherapy for elderly non-frail breast cancer patientswith an increased risk of relapse. Abstract Nr. 228, EBCC9-Programme book web-v2, Page 81, 2014

Loibl S, Blohmer J.U, Fasching P.A, Gerber B, Jackisch C, Kümmel S, Harbeck N, Mehta K.M, von Minckwitz G, Untch M: Response andprognosis after neoadjuvant chemotherapy in 1,051 patientswith infiltrating lobular carcinoma of the breast. Abstract Nr. 398, EBCC9-Programme book web-v2, Page 107, 2014

Fontanella C, Lederer B, Huober J, Gerber B, Mehta K.M, Nekljudova V, Gabe S, von Minckwitz G, Untch M, Loibl S: Effect of diabetesmellitus on early breast cancer patients receiving neoadjuvant therapy. Abstract Nr. 416, EBCC9-Programme book web-v2, Page 112, 2014

Fontanella C, Slaets L, Neven P, Loibl S, Vanoppen M, Bogaerts J, von Minckwitz G, Cameron D, Untch M, Bonnefoi H: Influence of bodymass index on long-termoutcome of breast cancer patients receiving neoadjuvant therapy - Combined results fromtheGBG(GermanBreast Group)and the EORTC cohorts. Abstract Nr. 417, EBCC9-Programme book web-v2, Page 112, 2014

DGGG / Senologie / DGHO

Laakmann E, Müller V, Fehm T, Möbus V, von Minckwitz G, Kaiser J, Loibl S, Witzel I: Brain Metastases in Breast Cancer Network Germany (BMBC): Eine multizentrische retrospektive und prospektive Datenbank und Biomaterialsammlung von Patientinnen mit Hirnmetastasen eines Mammakarzinoms. DGGG-Kongress in München, Geburtshilfe Frauenheilkd 2014; 74 - PO_Onko08_12

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kühn T: Validierung eines Nomogramms zur Prädiktion von Non-Sentinellymphknoten-Metastasen bei Patientinnen mit primär-systemischer Therapie (PST) – eine transSENTINA Substudie. DGGG-Kongress München, Geburtshilfe Frauenheilkd 2014; 74 - PO_Onko07_07

Noeding St., Forstbauer H., Wachsmann G., Ober A., Schneeweiss A., Christensen B., von Abel E., Grischke EM., Höffkes H.G., Klare P., Ko YD., Schmatloch S., Burchardi N., Loibl S., von Minckwitz G., Möbus V: GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs. Senologie 2014, Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A89

Laakmann E, Müller V, Fehm T, Möbus V, von Minckwitz G, Kaiser J, Loibl S, Witzel I: Brain Metastases in Breast Cancer Network Germany (BMBC): Eine multizentrische retrospektive und prospektive Datenbank und Biomaterialsammlung von Patientinnen mit Hirnmetastasen eines Mammakarzinoms. Senologie 2014, Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A73

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kühn T: Validierung eines Nomogramms zur Prädiktion von Non-Sentinellymphknoten-Metastasen bei Patientinnen mit primär-systemischer Therapie (PST) – eine transSENTINA Substudie. Senologie 2014, Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A75

Noeding St., Forstbauer H., Wachsmann G., Ober A., Schneeweiss A., Christensen B., von Abel E., Grischke EM., Höffkes H.G., Klare P., Ko YD., Schmatloch S., Burchardi N., Loibl S., von Minckwitz G., Möbus V: GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs. DGHO Hamburg 2014, Vortrag Nr V373, S. 89